Sanofi(US:SNY) Yahoo Finance·2026-02-08 09:27Group 1 - Sanofi is recognized as one of the best blue-chip stocks to buy, with plans for a €1 billion share buyback in 2026 following strong Q4 2025 results [1][6] - The company reported adjusted earnings per share of €1.53 and revenue of €11.3 billion, exceeding analyst expectations, driven by a 32.2% increase in Dupixent sales to €4.2 billion [2] - Despite the positive financial results, Sanofi's shares experienced a slight decline due to broader market volatility [2] Group 2 - CEO Paul Hudson indicated that profitable growth is anticipated to continue for at least five years, with increased investment in research and development to support this growth [3] - Sanofi operates globally in over 60 countries, focusing on immunology, oncology, rare diseases, and infectious diseases [4]